HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

High CCR5 expression in natalizumab-associated progressive multifocal leukoencephalopathy immune reconstitution inflammatory syndrome supports treatment with the CCR5 inhibitor maraviroc.

AuthorsLidia Stork, Wolfgang Brück, Amit Bar-Or, Imke Metz
JournalActa neuropathologica (Acta Neuropathol) Vol. 129 Issue 3 Pg. 467-8 (Mar 2015) ISSN: 1432-0533 [Electronic] Germany
PMID25604548 (Publication Type: Letter, Research Support, Non-U.S. Gov't)
Chemical References
  • CCR5 Receptor Antagonists
  • Cyclohexanes
  • Natalizumab
  • Receptors, CCR5
  • Triazoles
  • Maraviroc
Topics
  • B-Lymphocytes (metabolism)
  • CCR5 Receptor Antagonists (therapeutic use)
  • CD4-Positive T-Lymphocytes
  • CD8-Positive T-Lymphocytes (metabolism)
  • Cyclohexanes
  • Humans
  • Immune Reconstitution Inflammatory Syndrome (drug therapy, etiology, metabolism)
  • Leukoencephalopathy, Progressive Multifocal (drug therapy, etiology, metabolism)
  • Maraviroc
  • Multiple Sclerosis (drug therapy)
  • Natalizumab (therapeutic use)
  • Receptors, CCR5 (biosynthesis)
  • Triazoles

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: